KIF2C: A Protein Targeted for Cancer Treatment (G11004)

Target Name: KIF2C

NCBI ID: G11004

KIF2C

KIF2C: A Protein Targeted for Cancer Treatment

Kinesin-like protein KIF2C (isoform 1) is a protein that plays a crucial role in the transport of various molecules in the cell. It is a member of the Kinesin family, which is known for their ability to transport organelles and vesicles within cells. KIF2C is an isoform of KIF2C, which means that it has the same amino acid sequence as KIF2C but may have different levels of expression or function due to differences in the way the gene is transcribed or translated.

KIF2C is involved in a variety of cellular processes, including the transport of organelles, such as mitochondria, to the cytoplasm, and the transport of vesicles, such as the endoplasmic reticulum (ER) to the cytoplasm. It is also involved in the regulation of cellular processes such as cell division, apoptosis, and signaling pathways.

One of the unique features of KIF2C is its ability to interact with other proteins, including the protein kinase PDK4. This interaction between KIF2C and PDK4 is important for the regulation of cellular processes such as cell growth, differentiation, and survival.

KIF2C is also known for its role in the development and progression of various diseases, including cancer. It has been shown to be involved in the regulation of cellular processes that are often disrupted in cancer, such as the transport of nutrients to cells, cell division , and apoptosis.

In addition to its role in disease, KIF2C is also a potential drug target. Its involvement in cellular processes and its ability to interact with other proteins make it a promising target for small molecules and other therapeutic agents.

One approach to targeting KIF2C is the use of small molecules, such as those that can modulate its interaction with other proteins. One example of a small molecule that has been shown to interact with KIF2C is the drug and technology company's proprietary compound, CPI-061020.

In preclinical studies, CPI-061020 has been shown to inhibit the activity of KIF2C and reduce the migration and invasion of cancer cells. This suggests that it may be a useful agent for the treatment of various cancers.

Another approach to targeting KIF2C is the use of antibodies that can specifically recognize and target the protein. One example of an antibody that has been shown to interact with KIF2C is the monoclonal antibody (mAb) 152120.

In preclinical studies, 152120 has been shown to block the activity of KIF2C and reduce the migration and invasion of cancer cells. This suggests that it may be a useful agent for the treatment of various cancers.

In conclusion, KIF2C is a protein that plays a crucial role in the transport of various molecules in the cell. Its involvement in cellular processes and its ability to interact with other proteins make it a potential drug target and a promising agent for the treatment of various diseases. The use of small molecules and antibodies that can modulate its interaction with other proteins or specifically recognize and target the protein may be a promising strategy for the development of new treatments for a variety of diseases.

Protein Name: Kinesin Family Member 2C

Functions: In complex with KIF18B, constitutes the major microtubule plus-end depolymerizing activity in mitotic cells (PubMed:21820309). Regulates the turnover of microtubules at the kinetochore and functions in chromosome segregation during mitosis (PubMed:19060894). Plays a role in chromosome congression and is required for the lateral to end-on conversion of the chromosome-microtubule attachment (PubMed:23891108)

The "KIF2C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF2C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets